the our for XXXX you, financial and thank Thank you and update afternoon, everyone, and third quarter Kiki, corporate joining conference good results call.
going like and included value create would X to you see can earlier we this strategy conclusions efficacy meeting clear a we released we transformational in Cardiff signal context demonstrate data forward. on X, you a in which put small and the FDA both metastatic supportive the we and As expansion how an from relationship can for this and cancer, our with was colorectal indications.Today, from in Pfizer. August, highly strong with new data monotherapy KRAS-mutated cancer, Oncology. announced lead with our lung stage past programs cancer for all in of September, program In quarter our all Slide shareholder Then cell explain onvansertib in of pancreatic to
clear efficacy we single onvansertib with clinical chemotherapies drug Oncology and know, the meaning all times inhibitor include, of a multiple on publicly our therapies. combination indications.Second, the is The and these for onvansertib to is first and PLKX development, as shown for of X, companies. target from which our specific biotech Cardiff in onvansertib a across molecule we signals collection foremost, clinical strengths first-in-class are build agent only has in list for has Slide this value.As well-understood As listed tolerability these challenging cancer trials in
that we can patients our the the our indications onvansertib This in is Slide let of focus regimens. enables plans, all is and cash into financial are are with there pursue have to X, Oncology in program combine support first-line second-line patient common fact synergistically some in most in Third, standard address could targeting are that of third-party The metastatic large lines where of colorectal and to both many early therapy care first-line deadliest well cancer clear we the positively us and and have of good will we populations finally, cancer this.Fourth, Pfizer. impacted. and very methodical examples be cancer resources pancreatic stakeholders. [ our a for this colorectal that we And strategy And for ].As and believe RAS-mutated for to with objectives cancer. create thoughtful value in metastatic a be clear, lead runway go XXXX our Cardiff and show of we me FDA we X our primary includes the manner tolerated
the mid-XXXX. generate Ignite in trial working first-line CRDF-XXX data and FDA execute development are our has to the We from with clinical to agreed Pfizer closely that currently to plan clinical
play is our our inhibition an in cell pancreatic through continue investigator-initiated cancer, and generate rooted small larger Our role has PLKX a clinical to lung our cancer, conviction second plan in we additional manner do from objective objective trials third is in to which triple-negative in even breast trials.Finally, to cancer to therapy. cancer data that capital-efficient
programs, we decisions logic clinical other indications. with explore strong cancer promising we will for to combinations As commercial make and new data-driven have
from studies.By Our plans efforts value we for the create clinical we announced objectives, the development and our in these all significant perspective a move shareholder opportunity while given the focus of that can the reduce X. risk larger preclinical executing we we potential towards quarter on and are believe reward that third cost-effective Slide data current our of increasing to now the pursuing.Let's commercial stakeholders, plan
lead the summarizing of the in our accomplishments we're Here colorectal program quarter during third cancer. metastatic key
our into first-line a cancer.About treatment. not shared our series colorectal Phase were KRAS-mutated you in patients treated trial or who know, of trial As with from bevacizumab in bev second-line came clinical Xb/X second-line of August, metastatic we findings X/X in prior the their
this patient, second-line the our of includes strong which with drug on to responses saw standard onvansertib we bev-naïve For the care, bev. of combination
signal play onvansertib versus question, to and Specifically, tumor believe plant once XX% unknown. encouraged to the versus [ in analysis patients these response study tumor suggested Tempus us X controls a highly XXX engaged in called thereby who ignore.So investigated X patients mechanism answer X-fold strong from KRAS-mutated historical too setting. multiphase were both metastatic bev to Observing work colorectal median a strong that of patients setting.We this patients new bev-naïve to biopsy their objective action these led in tumor the we've is the bev-naïve asked clinical step, independent response action there had also our before a a this at controls finding preclinical to why as was that confirmed change the an cancer supply, had months observed of decreasing progressed first-line this ] patients. remained to only To to a patients that increase explains with restrict independent onvansertib conduct Phase disease data, in to is have by median through in underlying bev XX-month in patients a results tumor research why significantly clinical time doubling our we generating tumor's that not together treated positive growth.We science and second-line setting, program. analyzed treatment in first-line blood The with work mechanisms rate, next the in were around were bev exposed a that trial previously but were historical onvansertib Xb/X of populations. bev in patient consistent conclude observed resistance we bev-naïve months.We rate of bev-exposed bev-naïve, was And genomics clinical was preclinical XX%. this for in and for changed, trial PFS of of of XX the a the not This a and a showed data that next a demonstrated which on that their us
FDA we Now patients are and cancer.We armed where development program suggestion of in have onvansertib these the preclinical down the all population development opportunity findings, the June line, by RAS-mutated The impact a the first proposing metastatic clinical with our Type bev-naïve responded in this we a FDA colorectal to data meeting positively C to patient FDA suggested to plan where trials. X our of year. with up largest clinical the of and we clinical share move with
we randomized full approval data can approval confirmation. guidance the a clear for to both one The dose path or first provide efficacy from trial. FDA where CRDF-XXX, trial, and Then CRDF-XXX, registrational conduct provided trial, both will a subsequent and accelerated
response the Scientific Board, you the just package data includes from representative described, X Pfizer I FDA and conclusions know, Advisory with years shared FDA of in trial. we members the which CRDF-XXX Finally, full preclinical initially Cardiff conduct and us the ago. that clinical, Having of Ignite clinical full proposed invested to seen our they Pfizer Oncology first-line Pfizer.As development
every at the Chief Officer, goals. ensuring of that beneficial aligned Pfizer. internal with They gave scientific considers, Now Pfizer's potential each by along project, scrutiny members Ignite Scientific other are broader undergoes with key team partnership collaborations Pfizer mutually close and the
with the and relationship we onvansertib.This sites I'd next middle are economic our of in cancer development for their We which August, earlier-stage group In CRDF-XXX announced to plan on our November, from open to in now clinical full we support announced trials, pancreatic our X to States enrolling forward X. horsepower path importantly, will first-line planned to allows clinical maintains in be the programs, shortly highlighted while report first us this, XX leverage across in turn and Slide Cardiff of [ clinical patients As Oncology enrollment. the of to September, month, to thereafter metastatic our trial signals United ownership clinical anticipate setting. which efficacy Pfizer year.With like preliminary Ignite results of control our CRDF-XXX the execute ] trial, new planned
X X awaiting setting of ] partial PR.As September we [ data were metastatic patients as first onvansertib's The with in objective were still PDAC. our pancreatic PRs and the efficacy evaluate the XXXX, CRDF-XXX, of XX% achieved know, second-line the tolerability X of trial, reported patients scans. XX, ductal adenocarcinoma, XX confirmatory or an CRDF-XXX, or From of response cutoff of their you
As has of XX, their trial. response this scan, X-month therefore, patients, confirmed further November shown PR of patient a Xnd, these representing at now X on X today, deepening of the second
approaches onvansertib's trial this benchmark remaining of ] tumors median for biomarker another We second is X.X of discovery of first-line in months still for another X unconfirmed than of PDAC, months, indication.The encouraging effect an is reported months median much survival the is evaluated this evaluable X which on survival as treatment, are X.X about progression-free in since being scans all PFS, PR awaiting patients efficacy single second-line.Overall, confirmatory the is X agent. remain the where for a we yet which for signal longer strong pancreatic X a and X over [ months, on cancer for is metastatic median investigator-initiated historical who This months. in with progression-free indicating an patients, trial
design be Science potentially impact the highest. greatest when are possible recall opportunity This have showed after observed both XX tumor encouraging monotherapy days move Oregon trials, presented onvansertib Health these stage, a As the results we chances we call, to new to the treatment.Because Knight the trial that first-line to only in us investigator-initiated date conducted our the challenging to with to treatment at from earliest University from Institute. last biomarkers onvansertib diseases these Cancer patients September data & effects to to at responding first-line the of to of we with of enables study plan the you on
generate onvansertib as Center. the cancer. this we disease. trial from partial and forward disease.Our to and investigator-initiated we treats combination confirmed disease are Seeing assessed provides stable cell is allows patients a had to X this conducted in first have shrinkage lung on treated treatment Pittsburgh September, most signal the a in reported us at enrollment Of look X Finally, also standard a continue important, plans in data capital-efficient the regimen likely onvansertib But XXXX, small of refractory first in in cancer paclitaxel. of a trial onvansertib second-line at XX, current presented response, as of the progressive investigator University expectation onvansertib September, being response, patients XX% X been this one tumor, and clear September a with efficacy that partial path which monotherapy Medical include of trial. monotherapy confirmed lung small as extensive-stage a of cell the of challenging clinical The with care, approach is an data manner.In a with our to is future that in
it we'll becomes cancer when trial investigator-initiated that triple-negative available.Okay. the and from to continues enroll Finally, provide in trial breast data
and investigate programs new So is for objective But ongoing far, I've onvansertib. create discussed to indications our our our therapeutic to stakeholders, for plans. value third
X recent approved. is where process this breast ideal broader treatment or with should a hormone combination metastatic ovarian observed X to exploring Paclitaxel, we indications by breast setting.The liver, antimitotic with that treatment, breast X bev third I models XXXX. explore unmatched new the indications is highly Jamie cancer.We bev a represents in which given HR-positive of approach colorectal our first-line critical dramatic onvansertib to model Levine, These through additional the a PLKX aggressively kidney, can could receptor to XX% it the to cost-effective combination There an shows within this models HR-positive will example, from FDA cancer, extensive data xenograft cancer at will mitosis, the explore X also common financial cell go power at breast cancer. be each cancer cell This cancer, which role of Oncology, cancer. develop are a we response therapy, We onvansertib the Slide resistance for divides ] quarter onvansertib for [ an literature results. PLKX. onvansertib, the it synergistic, the of tumors first-line Slide positive, have cervical of For or the validate is includes making how second over CFO, the States and to example, HR-positive we combination, for this resistant a palbociclib share impact cases. and discovery with of to the form United combined most today of cancer committed in vision with that over To hormone agent, combinations.Now data cancer Jamie? is X. one suggesting agent tumor with through wild-type part I that combination combination to and on having in cells preclinical treatment.As and we results RAS overexpressing indicates we the data diagnosed treatment shown antimitotic common here give and about cancer been complete combination turn plays significant to breast models pre-clinical supports in the is this our agents cellular the paclitaxel look antimitotic Cardiff of patient-derived receptor know regression preclinical tumor is to in X.Breast XX% models In in on remain in some agents HR-positive lung, over believe using pre-clinical results drug
